GeneDx Holdings Corp. (NASDAQ: WGS) Announces Entry Into New Loan Agreement and Termination of Existing Credit Facility

Key Points for Investors

• New Loan Agreement: GeneDx Holdings Corp. has entered into a new Loan Agreement, which will be guaranteed by the company’s subsidiaries (the “Guarantors”) and secured by a first lien on substantially all assets of both the Company and the Guarantors.
• Minimum Liquidity Covenant: The agreement includes a minimum liquidity covenant requiring GeneDx to maintain at least \$50 million in liquidity.
• Default Provisions: If GeneDx defaults and the default is ongoing, lenders may declare all amounts outstanding under the Loan Agreement immediately due and payable.
• Termination of Previous Credit Agreement: The new Loan Agreement coincides with the termination and payoff of the Company’s previous credit facility (“Existing Credit Agreement”).
• Securities Information: The Company’s Class A common stock trades under the symbol WGS, and its warrants trade under WGSWW on NASDAQ.
• Forward-Looking Statements: The company has issued standard cautionary language regarding forward-looking statements, including the potential impacts of the new financing, business plans, industry risks, and uncertainties.
• Reporting and Compliance: The full text of the Loan Agreement will be made available as an exhibit to the Company’s upcoming Quarterly Report on Form 10-Q for the quarter ending March 31, 2026.

Details of the Loan Agreement

On February 27, 2026, GeneDx Holdings Corp. (the “Company”) entered into a material definitive Loan Agreement, which will be guaranteed by the Company’s subsidiaries. This new debt facility is secured by a first priority lien on substantially all assets of the Company and its Guarantors, providing lenders with significant collateral protection.

The Loan Agreement includes:

• Customary representations and warranties, as well as affirmative and negative covenants and events of default, all of which are standard in such financing arrangements.
• A minimum liquidity covenant of \$50 million. GeneDx must maintain this level of liquidity at all times, which helps ensure the Company’s solvency and operational flexibility.
• If an event of default occurs and continues, lenders have the right to accelerate the loan, making all outstanding amounts due immediately.

The Company highlights that the Loan Agreement’s details will be filed as an exhibit to its Quarterly Report on Form 10-Q for the three months ended March 31, 2026. Stakeholders are encouraged to review the full agreement when available to understand all terms and restrictions.

Termination of Existing Credit Facility

In connection with entering into the new Loan Agreement, GeneDx has terminated its previous credit agreement by paying off all amounts due under that facility. This move consolidates the Company’s debt structure and may offer improved terms or flexibility compared to the prior facility.

Potential Shareholder Impact

• Financial Flexibility: Entering into a new, secured loan agreement with a substantial liquidity covenant strengthens the Company’s balance sheet and may allow for greater operational flexibility and strategic initiatives.
• Risk Factors: The requirement to maintain \$50 million in liquidity imposes a discipline that may limit aggressive investments but also protects creditors and shareholders from overextension.
• Potential for Share Price Movement: Material changes in capital structure, such as replacing a previous credit facility with a new loan agreement, can be significant for shareholders and may affect the Company’s share price, depending on market perception of the new terms and the Company’s financial outlook.
• Warrants and Stock Information: The Company’s Class A common stock (WGS) and warrants (WGSWW) continue to be listed on NASDAQ, offering liquidity to investors and warrant holders.

Forward-Looking Statements

The Company has cautioned investors that this report contains forward-looking statements that are subject to risks and uncertainties, including the ability to implement business plans, changing industry dynamics, market size and growth, and the Company’s ability to pursue its new strategic direction. Actual results may differ from those expressed or implied in the forward-looking statements, and investors are urged to review the “Risk Factors” section of the Company’s most recent Annual Report on Form 10-K and other SEC filings for further information.

Signatory

The report is signed by Katherine Stueland, Chief Executive Officer of GeneDx Holdings Corp., dated March 2, 2026.

Disclaimer: This article is a summary and interpretation of public SEC filings by GeneDx Holdings Corp. and is provided for informational purposes only. It does not constitute investment advice or a recommendation to buy or sell securities. Investors should review the full SEC filings and consult with their financial advisors before making any investment decisions. The author and publisher assume no responsibility for any actions taken based on this information.

View GeneDx Holdings Corp. Historical chart here